ArticleFrontiers in oncology2021

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.

Min Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.